Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.
You may also be interested in...
AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program
AbbVie should appeal to long-term investors due to its sustainable business base and plan to issue and increase dividends over time, says CEO Richard Gonzalez.
Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III
Reata has terminated the Phase III BEACON trial for its chronic kidney disease hopeful bardoxolone methyl, partnered with Abbott, due to safety concerns.
As AbbVie Prepares To Launch, Some Wind Gets Knocked Out Of Its Sails
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.